Antiplatelet Therapy: Implications for Patient Management - Y8003


About Course #Y8003

Start Date: September 16, 2016

Expiration Date: September 16, 2019

Antiplatelet medications are commonly used in cardiovascular disorders and are among the most commonly utilized medications in the country. The drugs are sometimes used alone but other times are used in combination to achieve optimal benefits. With both intravenous and oral agents, the clinician must understand the interplay between intravenous and oral therapy and the nuances of dual therapy versus monotherapy.

This course is for clinicians who provide care to patients currently taking antiplatelet medications. The purpose of this course is to increase clinicians" knowledge of antiplatelet medications so that they can identify the optimal therapy and safely utilize these medications. The information in this course was current at the time of publication. Pharmacotherapy is rapidly changing, new pharmaceutical agents are continuously being developed and approved, and older agents are being investigated in new ways; therefore, the clinician should stay abreast of new medications and ongoing research findings and their implications in the delivery of patient care.

Universal Activity Number (UAN) - 0607-0000-16-011-H01-P

Type of Activity - Knowledge

Topic Designator - 01 - Disease State Management/Drug Therapy

Course Objectives

  • Describe the contemporary role of antiplatelet medications in patients with coronary, cerebrovascular, and peripheral vascular disorders.
  • Describe current controversies in the duration of dual antiplatelet therapy.
  • Identify similarities and differences between different antiplatelet agents.
  • Describe how a pharmacist can utilize the information to optimize patient outcomes.

About the Author(s)

C. Michael White, PharmD, FCP, FCCP, is professor and chair of the University of Connecticut School of Pharmacy's Department of Pharmacy Practice in Storrs, Connecticut and Codirector of the Health Outcomes, Policy, and Evidence Synthesis research group at UConn and Hartford Hospital in Hartford, Connecticut, which houses one of only 13 Agency for Healthcare Research and Quality designated Evidence-Based Practice Centers.

Course Disclosures

  • Courses must be completed on or before the expiration date noted in the course description above.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools' policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.

  • bvseo_sdk, p_sdk, 3.2.0
  • CLOUD, getContent, 90.52ms
  • bvseo-msg: HTTP status code of 404 was returned;